awmsg logo



daptomycin (Cubicin®)


Reference No. 2935

Publication date:
01/04/2016


Appraisal information

daptomycin (Cubicin®) 350 mg powder for solution for infusion
daptomycin (Cubicin®) 500 mg powder for solution for infusion


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 24/03/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, daptomycin (Cubicin®) cannot be endorsed for use within NHS Wales for the treatment of paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections.
Statement of Advice (SOA)
Download